Navigation Links
New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics

This exciting clinical study is the best news that we have been waiting on for the past four years to prove the deposition of the medication through Sinus Dynamics.

Westlake Village, CA (PRWEB) March 19, 2009 -- Most ENT's and physicians have prescribed Sinus Dynamics and always asked if it would be better to have a clinical study done on the amount of medication deposited and penetrated into the sinuses. Now, fantastic news as a new clinical study proves the Sinus Dynamics treatment to be 82.9% successful for treatment of pre-sinus surgery, post-sinus surgery, acute and chronic sinusitis.

"I encourage everyone to please spend a few minutes to read the attached study ( and familiarize yourself with the facts that are in the study. After reading the attached, I am sure you would be able to better understand why the Sinus Dynamics treatment is the most effective treatment compared to any other treatment (Sinus Wash, Sinus Spray, oral Antibiotics and medications) for sinusitis. Now you can share this great news with everyone who has sinusitis or a sinus infection and needs fast and proven treatment to overcome their sinusitis and sinus infection problems for good."

As you read this study, it will show you that Sinus Dynamics has the smallest particle size in the industry and is able to deposit the medications into the sinuses better than any other Sinusitis or sinus infection products without any side effects. Also, in order to have the best results in topical treatments of sinusitis, you need to have a particle size of 3.2 mmhg, and Sinus Dynamics is the only treatment that meets this requirement (

The comprehensive study was published in August of 2008 and was conducted by clinical research physicians who are on staff with three, prominent, American medical universities. When compared to any other aerosolized therapies available in the medical industry, the study fully confirms that the smaller size of the mist particle of the Sinus Dynamics SinusAero Nebulizer penetrates the ostium for achieving topical deposition of medications on the mucosa of the paranasal sinus cavities; including the hard-to-reach maxillary sinus.

Additionally, the study discusses the fact that the deposition of the medication on the sinus lining was the same whether or not the patient had an FESS procedure (FESS stands for Functional Endoscopic Sinus Surgery). And, that the rate of recovery from the patient's acute or chronic sinusitis was the same using the Sinus Dynamics therapy for patients who had FESS procedures performed on them, and for those who did not. Please see the last paragraph on page one of the study where Sinus Dynamics is mentioned.

Also, all ENT's and doctors that needed more information in prescribing Sinus Dynamics or the ENT's that might have needed more clinical proof to show them the amount of the penetration and deposition of the medication to the sinuses are prescribing more of the Sinus Dynamics treatment for their Sinusitis patient's more than ever.

A quick reference that would help explain this matter to the prescribers are as follows:

  • The 6 studies that are in the Sinus Dynamics Clinical study site shows that Topical treatment is effective in treatment of Sinusitis.
  • The new attached study ( features the most proof that the Sinus Dynamics treatment has the smallest particle size, and because of this reason, the medication can be delivered deeper, while depositing more of the medication into the sinuses for better treatment of Sinusitis and Sinus Infection.
  • 82.9% success rate in treatment of sinusitis and Sinus Infection through Sinus Dynamics particle size.
Sinusitis is a chronic medical condition that can affect up to 38 million people each year. Most sinusitis and allergy suffers will become frustrated from the numerous treatments that they have used, including surgery, which may result in little to no improvement. With an 82.9% success rate, the Sinus Dynamics program has added 18 new topical medications which are combinations of Antibiotics, Anti-Fungal, and anti-inflammatory.

The Sinus Dynamics program is a unique form of treatment. Thousands of patients have at last found the relief that they have been longing for from their ongoing allergies and sinusitis infections with the Sinus Dynamics program in the five years since it has begun. Please check the testimonials on

If a sinusitis patient is tired of being disappointed by the continuous failing sinusitis treatments and wants to finally receive that relief from sinusitis and allergy problems, the Sinus Dynamics program is easy to use and comes with detailed instructions as well as customer service support to answer any questions that you may have. Sinus Dynamics works with most insurance companies and will handle the prescription from when it is received through handling all insurance relations. Mainly ENT's and Allergists in North America use the Sinus Dynamics program, though any physician may order the treatment for their sinusitis and allergy patients. Select antibiotics, anti-fungals and anti-inflammatories are offered to help relieve patients of their symptoms of sinusitis and allergies. Sinus Dynamics can be visited on the web at or reached toll free at 877-447-4276.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
Related Image:
New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief  through Sinus Dynamics 
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen ... plastic surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, ... giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global ...
(Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... Innovaacom, a leading provider of medical ... survey of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, ... quality online and face-to-face education for pharmacists who are fast becoming the new ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 NHS Supply ... 20 TrueBeam™ machines from Varian Medical Systems (NYSE: ... program to replace older machines and institute modern ... UK,s public hospitals. The order, placed in September, ... licenses for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
Breaking Medicine Technology: